Brofaromine

Brofaromine

Brofaromine
Systematic (IUPAC) name
4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
Clinical data
Legal status
  • (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Protein binding 98%
Biological half-life 9-14 hours
Identifiers
CAS Registry Number  Y
ATC code None
PubChem CID:
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  Y
Chemical data
Formula C14H16BrNO2
Molecular mass 310.186 g/mol
 Y   

Brofaromine (Consonar) is a reversible inhibitor of monoamine oxidase A discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.[2]

Brofaromine also has serotonin reuptake inhibitory properties and its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs.

Pharmacology

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

References

  1. ^ US Patent 4210655
  2. ^ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology 20 (3): 226–47.   Free full text